Business Description
Enorama Pharma AB
ISIN : SE0008216329
Compare
Compare
Traded in other countries / regions
ERMA.Sweden IPO Date
2016-06-10Description
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.4 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 2.68 | |||||
Beneish M-Score | 2.24 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -50.7 | |||||
3-Year EBITDA Growth Rate | 30.7 | |||||
3-Year EPS without NRI Growth Rate | -4.2 | |||||
3-Year FCF Growth Rate | 33.9 | |||||
3-Year Book Growth Rate | 16.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.33 | |||||
9-Day RSI | 60.72 | |||||
14-Day RSI | 58.02 | |||||
6-1 Month Momentum % | 4.49 | |||||
12-1 Month Momentum % | -12.1 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.95 | |||||
Quick Ratio | 0.46 | |||||
Cash Ratio | 0.24 | |||||
Days Inventory | 410.56 | |||||
Days Sales Outstanding | 707.12 | |||||
Days Payable | 496.71 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -90.7 | |||||
Shareholder Yield % | -22.42 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -635.08 | |||||
Operating Margin % | -6282.99 | |||||
Net Margin % | -6338.66 | |||||
FCF Margin % | -5345.82 | |||||
ROE % | -227.7 | |||||
ROA % | -119.33 | |||||
ROIC % | -152.24 | |||||
ROC (Joel Greenblatt) % | -4035.65 | |||||
ROCE % | -186.4 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 169.44 | |||||
PB Ratio | 8.84 | |||||
EV-to-EBIT | -4.32 | |||||
EV-to-EBITDA | -4.72 | |||||
EV-to-Revenue | 269.64 | |||||
EV-to-FCF | -5.04 | |||||
Earnings Yield (Greenblatt) % | -23.15 | |||||
FCF Yield % | -19.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enorama Pharma AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 0.67 | ||
EPS (TTM) (kr) | -0.95 | ||
Beta | 0 | ||
Volatility % | 224.78 | ||
14-Day RSI | 58.02 | ||
14-Day ATR (kr) | 0.325834 | ||
20-Day SMA (kr) | 2.707 | ||
12-1 Month Momentum % | -12.1 | ||
52-Week Range (kr) | 1.680808 - 8.484848 | ||
Shares Outstanding (Mil) | 60.47 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Enorama Pharma AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Enorama Pharma AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Enorama Pharma AB Frequently Asked Questions
What is Enorama Pharma AB(OSTO:ERMA)'s stock price today?
The current price of OSTO:ERMA is kr3.05. The 52 week high of OSTO:ERMA is kr8.48 and 52 week low is kr1.68.
When is next earnings date of Enorama Pharma AB(OSTO:ERMA)?
The next earnings date of Enorama Pharma AB(OSTO:ERMA) is 2024-08-21.
Does Enorama Pharma AB(OSTO:ERMA) pay dividends? If so, how much?
Enorama Pharma AB(OSTO:ERMA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |